methyl 2-(4-formylbenzamido)acetate | 849015-82-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-formylbenzamido)acetate
• 英文别名: 4-[[(methoxycarbonylmethyl)amino]carbonyl]benzaldehyde；methyl 2-[(4-formylbenzoyl)amino]acetate
• CAS: 849015-82-3
• 化学式: C₁₁H₁₁NO₄
• 分子量: 221.213
• InChiKey: QAWAFMVTBINFEL-UHFFFAOYSA-N

物化性质

• 沸点：
  427.5±30.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  72.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-formylbenzamido)acetate 在 水 、 溶剂黄146 、 sodium sulfate 、 sodium hydroxide 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 24.0h， 生成 [4‐({[(1S*,2R*)‐2‐phenylcyclopropyl]amino}methyl)benzoyl]glycine
  参考文献：
  名称：

  10.1002/ardp.202400450

  摘要：

  AbstractEpigenetic modulators such as lysine‐specific demethylase 1 (LSD1) and histone deacetylases (HDACs) are drug targets for cancer, neuropsychiatric disease, or inflammation, but inhibitors of these enzymes exhibit considerable side effects. For a potential local treatment with reduced systemic toxicity, we present here soft drug candidates as new LSD1 and HDAC inhibitors. A soft drug is a compound that is degraded in vivo to less active metabolites after having achieved its therapeutic function. This has been successfully applied for corticosteroids in the clinic, but soft drugs targeting epigenetic enzymes are scarce, with the HDAC inhibitor remetinostat being the only example. We have developed new methyl ester‐containing inhibitors targeting LSD1 or HDACs and compared the biological activities of these to their respective carboxylic acid cleavage products. In vitro activity assays, cellular experiments, and a stability assay identified potent HDAC and LSD1 soft drug candidates that are superior to their corresponding carboxylic acids in cellular models.

  DOI：

  10.1002/ardp.202400450
• 作为产物：
  描述：

  甘氨酸甲酯盐酸盐 、 对醛基苯甲酸 在 N-甲基吗啉 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二甲基亚砜 为溶剂， 反应 16.0h， 以570 mg的产率得到methyl 2-(4-formylbenzamido)acetate
  参考文献：
  名称：

  Cyclopropylamines as LSD1 inhibitors

  摘要：

  这项发明涉及环丙胺衍生物用于调节，特别是抑制赖氨酸特异性去甲基化酶1（LSD1）活性的用途。适当地，本发明涉及环丙胺衍生物在癌症治疗中的应用。

  公开号：

  US09346840B2

文献信息

• [EN] IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] DÉRIVÉS IMIDAZO [4,5-B] PYRIDINE COMME MODULATEURS D'ALK ET DE JAK POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS
  申请人：CEPHALON INC

  公开号：WO2013116291A1

  公开（公告）日：2013-08-08

  This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

  这项申请涉及到本文所定义的Formula I化合物及/或其盐。此申请进一步涉及到使用这些化合物和/或其盐的组合物和方法。Formula I化合物可用作ALK和JAK调节剂，用于治疗增殖性疾病。
• CYCLOPROPYLAMINES AS LSD1 INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20140371176A1

  公开（公告）日：2014-12-18

  This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.

  本发明涉及使用环丙胺衍生物来调节，特别是抑制赖氨酸特异性去甲基化酶1（LSD1）的活性。适当地，本发明涉及使用环丙胺衍生物治疗癌症。
• Cinnamoyl compound and use of the same
  申请人：Tomigahara Yoshitaka

  公开号：US20060211680A1

  公开（公告）日：2006-09-21

  The present invention relates to a cinnamoyl compound represented by the formula (I):

  本发明涉及一种由式(I)表示的肉桂酰化合物。
• Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders
  申请人：Cephalon, Inc.

  公开号：US20140350011A1

  公开（公告）日：2014-11-27

  This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

  本申请涉及公式I所定义的化合物和/或其盐。本申请还涉及使用这些化合物和/或其盐的组合物和方法。公式I的化合物可用作ALK和JAK调节剂，用于治疗增生性疾病。
• Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders
  申请人：Cephalon, Inc.

  公开号：US09238656B2

  公开（公告）日：2016-01-19

  This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

  本申请涉及公式I所定义的化合物及/或其盐。本申请还涉及使用这些化合物和/或其盐的组合物和方法。公式I的化合物可用作ALK和JAK调节剂，用于治疗增殖性疾病。